Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl June

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Scientific American|March 2, 2012
Blocking HIV's attackCarl June, Bruce Levine
Current Opinion in HIV and AIDS|January 19, 2011
Chemokine receptor 5 knockout strategiesPaula Cannon, Carl June
Nature Biotechnology|July 12, 2012
T-cell therapy at the thresholdCarl June, Steven A Rosenberg, Michel Sadelain, et al.
Journal of Cancer|July 1, 2011
Chimeric Antigen Receptor Therapy for B-cell MalignanciesDavid L Porter, Michael Kalos, Zhaohui Zheng, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 12, 2025
From concept to cure: The evolution of CAR-T cell therapyKisha K Patel, Mito Tariveranmoshabad, Siddhant Kadu, et al.
British Journal of Haematology|September 10, 2016
The cytological features of CAR(T) cellsSarah Brooks, Noelle Frey, David Porter, et al.
Journal of Translational Medicine|December 14, 2007
Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinomaRenato Lenzi, Robert Edwards, Carl June, et al.
Blood|February 7, 2004
Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activityYi Zhang, Gerard Joe, Jiang Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancersAfrica Wallace, Veena Kapoor, Jing Sun, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 12, 2025
DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicityHuaishan Wang, Shujing Liu, Prithvi Sinha, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Scientific American|March 2, 2012
Blocking HIV's attackCarl June, Bruce Levine
Current Opinion in HIV and AIDS|January 19, 2011
Chemokine receptor 5 knockout strategiesPaula Cannon, Carl June
Nature Biotechnology|July 12, 2012
T-cell therapy at the thresholdCarl June, Steven A Rosenberg, Michel Sadelain, et al.
Journal of Cancer|July 1, 2011
Chimeric Antigen Receptor Therapy for B-cell MalignanciesDavid L Porter, Michael Kalos, Zhaohui Zheng, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 12, 2025
From concept to cure: The evolution of CAR-T cell therapyKisha K Patel, Mito Tariveranmoshabad, Siddhant Kadu, et al.
British Journal of Haematology|September 10, 2016
The cytological features of CAR(T) cellsSarah Brooks, Noelle Frey, David Porter, et al.
Journal of Translational Medicine|December 14, 2007
Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinomaRenato Lenzi, Robert Edwards, Carl June, et al.
Blood|February 7, 2004
Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activityYi Zhang, Gerard Joe, Jiang Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancersAfrica Wallace, Veena Kapoor, Jing Sun, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 12, 2025
DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicityHuaishan Wang, Shujing Liu, Prithvi Sinha, et al.
Pageof 2